Over the course of the next few months, Krishnakumar is likely to join the pharma company as an Executive Director overseeing operations
Pharma companies that bottomed out in 2019 with all data integrity issues getting solved are now totally thriving with countries that were spending less % of GDP on it are now doing it and storing drugs.
"In the current scenario, we can never say that the worst is over in the equity markets, any negative news on the geopolitical level will take it down. I am not worried about the COVID-19 situation though."
Bhan is of the view that the improvement in the pharma sector in the last 4-5 months is also the function of improvement in the fundamentals of the companies.
At present, 70 percent of India’s API requirement is sourced from China, while for antibiotics in particular, the dependence is over 90 percent
The Pfizer deal at roughly $2 billion deal translates into per dose price of $20. Competitors will, therefore, be forced to offer their coronavirus vaccine in a similar price range
A committee has been set up under the health secretary and a report is expected in the next 21 days.
As per reports, Fosun had made a formal proposal to purchase stake in two companies.
The fund aims to bring 2-4 new antibiotics to market this decade that will save patients' lives.
Let the axe first fall on low quality non-essential imports like cheap toys. Then have a graded strategy of domestic manufacturing of items according to how important they are and what scope there is for value addition
“Anthem Biosciences is looking to tap investors, primarily private equity funds & sell a 10 percent stake in the firm and raise around $100 million. If plans fructify, this would value the firm at a billion dollars," a source said.
Like many countries, India relies on China for products such as electronic components and drug ingredients because it cannot make them or source them elsewhere as cheaply, company and industry figures say.
The sector to watch still remains pharma. The valuation is still way off the valuations the sector governed even around 5 years back, thus creating an upward space.
In the first stage, subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed within 30 days from the execution date, subject to certain conditions precedent.
Experts feel that the current environment is more conducive for the Pharma sector and the rally is likely to continue in some of the names.
Some experts feel commercial lease rentals may come under pressure in a few locations and may witness a decline of at least 20 percent.
The Carlyle-Hari Babu consortium is in advanced stages of negotiations to buy out Hyderabad-based API ( active pharmaceutical ingredients) maker Ra Chem Pharma from majority stakeholder and parent Micro Labs.
Investors should, therefore, patiently wait and get into sectoral leaders to prevent wealth erosion in the coming months, says Umesh Mehta.
The company's tablets are available in 54 mg dose in bottle count size of 90, and 160 mg dose in bottle count sizes of 90 and 500
Aurobindo Pharma on Tuesday said the US health regulator has decided that the inspection classification of company's injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI).
The product is a generic version of Ancobon Capsules, 250 mg and 500 mg, of Bausch Health US, LLC, the Bengaluru- headquartered pharmaceutical company said in a statement.
The panic created by COVID-19 has taken a heavy toll on most sectors but pharma companies seem to have withstood the carnage, with some stocks delivering healthy returns during this period.
Sectorally, the action was seen in healthcare, IT, Realty, Bankex, Telecom, and Auto stocks which are trading with gains of over 4 percent each.
Chloroquine and a similar drug, hydroxychloroquine, showed encouraging signs in small, early tests against the coronavirus. But the drugs have major side effects, one reason scientists don’t want to give them without evidence of their value, even in this emergency.